Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers

Acta Haematologica

Volumn 134, Issue 4, 2015, Pages 208-214

  Novák, Martin ^a   Procházka, Vit ^a   Turcsányi, Peter ^b   Papajík, Tomáš ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Binet stage; Chronic lymphocytic leukemia; Programmed cell death 1

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD DONOR; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERY ELDERLY; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84930921572     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000381468     Document Type: Article

References (37)

1. Ishida Y, Agata Y, Shibahara K, Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
2. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126.
3. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003; 33: 2706-2716.
4. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T: Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
5. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A: Blockade of PDL1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006; 119: 317-327.
6. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
7. Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K: Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigenspecific T cells. Gene Ther 2014; 21: 262-271.
8. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
9. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K: PDL2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
10. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L: Tumor associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
11. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
12. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
13. Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI, Dong H, Kwon ED, Novak A, Markovic SN, Pittelkow MR, Witzig TE, Ansell SM: B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2012; 114: 2149-2158.
14. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, Jaksic O, Fedele G, Inghirami G, Gaidano G, Malavasi F, Deaglio S: The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 2013; 98: 953-963.
15. Grzywnowicz M, Zaleska J, Mertens D, Tomczak W, Wlasiuk P, Kosior K, Piechnik A, Bojarska-Junak A, Dmoszynska A, Giannopoulos K: Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia. PloS One 2012; 7:e35178.
16. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MP, Montserrat E, Rai KR, Kipps TJ: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood 2008; 111: 5446-5456.
17. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F: The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 144: 3367-3375.
18. Stevenson BK, Krysov S, Davies AJ, Steele AJ, Packham G: B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
19. Wienster A: Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 88-96.
20. Young RM, Staudt LM: Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-243.
21. Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, Hofmann D, Surova E, Follo M, Kohler F, Wardemann H, Zirlik K, Veelken H, Jumaa H: Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012; 489: 309-312.
22. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
23. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
24. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freemann GJ: Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
25. Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, John C. Byrd JC, Michael A. Caligiuri MA: The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutical target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294.
26. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
27. Han Y, Wu J, Bi L, Xiong S, Gao S, Yin L, Jiang L, Chen CH, Yu K, Zhang S: Malignant B cells induce the conversion of CD4+CD25-T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PloS One 2011; 6:e28649.
28. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, Joyce RM, Wellenstein K, Keefe W, Schickler M, Rotem-Yehudar R, Kufe D: PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cells/myeloma fusion vaccine. J Immunother 2011; 34: 409-418.
29. Azuma T, Yao S, Zhu G, Flies SJ, Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111: 3635-3643.
30. Nunes CT, Wong R, Mason M, Fegan C, Man S, Pepper C: Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012; 18: 678-687.
31. Kedmi M, Avigdor A, Nagler A: Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities. Acta Haematol 2015; 133: 129-135.
32. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D: PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKC theta. FEBS Lett 2004; 574: 37-41.
33. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, Tamada K, Chen L: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65: 1089-1096.
34. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus CH, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
35. Seetharamu N: The state of the art in nonsmall cell lung cancer immunotherapy. Semin Thorac Cardiovasc Surg 2014; 26: 26-35.
36. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
37. Soria JC, Cruz C, Bahleda R, Delord JP, Horn L, Herbst RS, Gettinger S: Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur Cancer Congr 2013; 49:S798.